Feature Papers for Kidney and Dialysis: Advances in Nephrology and Dialysis—Series II

A special issue of Kidney and Dialysis (ISSN 2673-8236).

Deadline for manuscript submissions: 31 December 2024 | Viewed by 2579

Special Issue Editor

Special Issue Information

Dear Colleagues:

Until recently, nephrology has been unable to keep pace with oncology, cardiology, or rheumatology in the inexhaustible pipeline of new treatment options tested in an ever-increasing number of randomized controlled trials. In recent years, we have witnessed a dramatic increase in the interest in treating chronic kidney disease, e.g., diabetic kidney disease, glomerular disease, or autosomal dominant polycystic kidney disease. This has also been aimed more generally at the progression of chronic kidney disease and the complications of chronic kidney disease, such as anemia or hyperkalemia. This progress has led to changing paradigms, as reflected by several recently published KDIGO guidelines, which now need to be updated much more frequently than before. To personalize treatment, we also need better diagnostic methods, including validated biomarkers reflecting the activity of the disease (including response to treatment) and predicting outcomes.

This new edition of Special Issue in Kidney and Dialysis aims is to cover most of these areas through feature reviews, original articles and keeping the reader updated on the recent progress in nephrology and dialysis.

The topics of this Special Issue include but are not limited to:

  • Biomarkers;
  • The progression of chronic kidney disease;
  • Cardiovascular and renal risk in CKD;
  • COVID-19 and the kidney;
  • Onconephrology;
  • Kidney function;
  • Chronic kidney disease (CKD), complications, and nutrition;
  • Acute kidney injury (AKI)/critical care;
  • Diabetic kidney disease;
  • Glomerulonephritis;
  • Cardionephrology;
  • Pregnancy and CKD;
  • Hypertension and nephrology;
  • ADPKD;
  • Renal vasculitis;
  • Lupus nephritis;
  • Renal and renovascular hypertension;
  • Kidney amyloidosis;
  • Hereditary kidney disease;
  • Renal ischemia;
  • Kidney stones;
  • Dialysis, hemodialysis (HD), peritoneal dialysis (PD);
  • Long-term outcomes;
  • Renal recovery;
  • Treatment of kidney disease;
  • Dietary management and medication;
  • Renal replacement therapy;
  • Kidney transplantation;
  • New diagnosis methods and technologies for kidney function and disease;
  • Renal imaging;
  • Renal ultrasound.

We hope this topic is engaging and invite you to send a tentative title and short abstract to our editorial office (kidneydial@mdpi.com) for evaluation before submission. Please note that selected papers are still subject to a thorough peer review.

We look forward to receiving your excellent work.

Prof. Dr. Vladimir Tesar
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Kidney and Dialysis is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetic kidney disease
  • chronic kidney disease
  • anemia
  • biomarker
  • dialysis

Related Special Issue

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 781 KiB  
Article
Incidence, Risk Factors, and Consequences of Acute Kidney Injury in Patients Undergoing Esophageal Cancer Surgery: A Historical Cohort
by Ilaria Godi, Paolo Feltracco, Giulia Lorenzoni, Alessio Antonelli, Renato Salvador, Dario Gregori, Ivo Tiberio and Michele Valmasoni
Kidney Dial. 2024, 4(2), 93-104; https://doi.org/10.3390/kidneydial4020007 - 03 Apr 2024
Viewed by 369
Abstract
Background: Limited data exist on postoperative acute kidney injury (AKI) in patients who have undergone esophageal cancer surgery. The purpose of this study was to evaluate the incidence, risk factors, and consequences of postoperative acute kidney after esophagectomy. Methods: This was a retrospective [...] Read more.
Background: Limited data exist on postoperative acute kidney injury (AKI) in patients who have undergone esophageal cancer surgery. The purpose of this study was to evaluate the incidence, risk factors, and consequences of postoperative acute kidney after esophagectomy. Methods: This was a retrospective cohort study. The study was conducted in a tertiary specialized cancer center in Italy. All patients undergoing elective esophageal cancer surgery between 2016 and 2021 were included in the study. AKI was defined according to Kidney Disease Improving Global Outcomes criteria (both serum creatinine and urine output), within 48 h after surgery. Preoperative and intraoperative data were registered. We also collected data concerning progression of AKI, need for renal replacement therapy, mortality, and medical (pulmonary, cardiovascular, septic) and surgical complications within 30 days from surgery, as well as length of hospital stay. Results: Incidence of postoperative AKI was 32%. The independent risk factors were body mass index and the use of an invasive surgical approach. Persistent AKI accounted for 15% of the cases and it was associated with increased risk of major cardiovascular events (odds ratio 4.14, 95% CI 1.05–15.8, p-value 0.036), pulmonary complications (OR 3.67, 95% CI 1.04–14.9, p-value 0.050), and increased length of hospital stay (AME 7.2, 0.5–13.9, p-value 0.035). Conclusions: Postoperative AKI is common after esophageal cancer surgery. BMI and a totally invasive surgical approach are independent risk factors. Persistent AKI lasting more than 48 h increased the risk for any cardiovascular or pulmonary complications, with prolonged length of hospital stay. Full article
Show Figures

Figure 1

Review

Jump to: Research

10 pages, 245 KiB  
Review
One-Size-Does-Not-Fit-All: The Case of Incremental Hemodialysis
by Francesco Gaetano Casino and Carlo Basile
Kidney Dial. 2024, 4(1), 27-36; https://doi.org/10.3390/kidneydial4010003 - 10 Jan 2024
Viewed by 861
Abstract
Conventional hemodialysis (HD) (a 4 h session three times a week) is not appropriate for everyone and is excessive in the presence of substantial residual kidney function (RKF). However, it can be safely replaced by a softer incremental approach guided by the urea [...] Read more.
Conventional hemodialysis (HD) (a 4 h session three times a week) is not appropriate for everyone and is excessive in the presence of substantial residual kidney function (RKF). However, it can be safely replaced by a softer incremental approach guided by the urea kinetic model (UKM), starting with one or two sessions a week. Observational data suggest that RKF may be lost less quickly if dialysis is initiated less frequently than 3 times a week. Incremental HD means that, in the presence of substantial RKF, kidney replacement therapy can begin with low doses and/or frequencies, which, however, must be adequately increased to compensate for any subsequent losses of RKF, keeping the total clearance level (kidney + dialysis) always above the minimum levels of adequacy. In HD, there are complexities in combining the dialysis dose with RKF, but tools have been developed to facilitate this issue. The literature findings lend support to the safety of incremental HD and highlight the potential for this method to be implemented as a new standard of care in dialysis patients with substantial RKF. Ongoing and future trials will likely generate further evidence of the clinical and healthcare benefits of incremental HD in routine practice. Full article
12 pages, 1069 KiB  
Review
Urgent-Start Peritoneal Dialysis: Current State and Future Directions
by Braden Vogt and Ankur D. Shah
Kidney Dial. 2024, 4(1), 15-26; https://doi.org/10.3390/kidneydial4010002 - 04 Jan 2024
Cited by 1 | Viewed by 909
Abstract
Urgent-start peritoneal dialysis (USPD) is defined as peritoneal dialysis initiated within 14 days of catheter insertion. In this review, the authors describe the most recent data on USPD, including outcomes, complications, barriers to implementation, and areas for future research. Outcomes appear similar between [...] Read more.
Urgent-start peritoneal dialysis (USPD) is defined as peritoneal dialysis initiated within 14 days of catheter insertion. In this review, the authors describe the most recent data on USPD, including outcomes, complications, barriers to implementation, and areas for future research. Outcomes appear similar between catheter insertion techniques, so patient factors and institutional workflow should guide practice. Mechanical complications may occur at a higher rate in USPD, but it does not impact technique survival or mortality. Infectious complications appear unchanged in USPD, and there may be fewer complications compared to urgent-start hemodialysis. Barriers to implementation are multifactorial, including physician and staff unfamiliarity and lack of institutional support. A significant limitation within the field includes lack of uniform terminology and definitions. Full article
Show Figures

Figure 1

Back to TopTop